Matching geography Reports matching your search in: Join Alert Me now!Receive bi-weekly email alerts on new market research Sign up today!
|
CNS/Neurology: market research reports
Neurology and the CNS is the branch of science dealing with anatomy, function, diagnosis and treatment of disorders and disease affecting the central nervous system (brain and spinal cord). Neuroscience medicine includes but is not limited to the study and treatment of Alzheimer’s disease, major depressive disorder, schizophrenia, Parkinson’s disease, epilepsy/seizures, migraine, insomnia/sleep disorders, bipolar disorder, and ADHD.
A neurologist is a medical doctor that specializes in the diagnosis, treatment and management of illnesses affecting the brain, spinal cord, and nervous system. Neurologists must complete at least three years of specialized training in neurology, after completing medical school. A neurosurgeon must go through much more extensive and rigorous schooling and training. On top of diagnosing and treating neurological disorders, neurosurgeons can also perform surgery on the brain, spinal cord, and nerves.
Pharmaceuticals in CNS/Neurology are one of leading fields in medicine in terms of funding and research. On top of growing patient numbers, there remains a comparatively high unmet need in treatment of many neurological diseases. With the potential of being one of the most lucrative therapy areas in the future pharmaceutical Industry, Alzheimer's disease offers the greatest commercial opportunity for pharmaceutical companies in neurology. Many of the therapeutic drugs used to treat CNS/Neurological disorders have lost their patent protection or market exclusivity, leading to greater research and market opportunities for competing pharmaceutical and medical device companies. Despite the widespread use of CNS drugs, knowledge of these agents is limited due to the anatomic and neurochemical complexity of the brain and spinal cord.
CNS/Neurology market research reports and industry analysis
|
|
$4,650.00
|
Neurology and Neurosurgery
1/1/2013 | published by: Apollo Managed Care, Inc.
... criteria guidelines for outpatient and inpatient tests and procedures with indications, medical necessity coverage criteria, authoritative references and resources ++ Alzheimer disease & ADHD page clinical guidelines - both with extensive references and resource materials.
|
more...
|
$149.00
|
|
|
$2,500.00
|
Astrocytoma Global Clinical Trials Review, H2, 2012
12/28/2012 | published by: GlobalData
... to the clinical trials on Astrocytoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of ...
|
more...
|
$2,500.00
|
EpiCast Report: Epilepsy Epidemiology Forecast to 2022
12/28/2012 | published by: GlobalData
... collection of brain dysfunction disorders characterized by recurrent and unpredictable seizures. The prevalence of epilepsy varies among countries due to a mosaic of economic, political, and social differences. GlobalData epidemiologists expect that the number of ...
|
more...
|
$6,995.00
|
Dementia – Pipeline Review, H2 2012
12/26/2012 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dementia. Dementia - Pipeline Review, Half Year is built using data and information ...
|
more...
|
$2,000.00
|
Nicotine Addiction – Pipeline Review, H2 2012
12/26/2012 | published by: Global Markets Direct
... Nicotine Addiction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nicotine Addiction. Nicotine Addiction - Pipeline Review, Half Year is ...
|
more...
|
$2,000.00
|
Anxiety Disorders – Pipeline Review, H2 2012
12/26/2012 | published by: Global Markets Direct
... Anxiety Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anxiety Disorders. Anxiety Disorders - Pipeline Review, Half Year is ...
|
more...
|
$2,000.00
|
Brain Injury – Pipeline Review, H2 2012
12/26/2012 | published by: Global Markets Direct
... Brain Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Brain Injury. Brain Injury - Pipeline Review, Half Year is ...
|
more...
|
$2,000.00
|
Addiction – Pipeline Review, H2 2012
12/26/2012 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Addiction. Addiction - Pipeline Review, Half Year is built using data and information ...
|
more...
|
$2,000.00
|
Other Neurologic Disorders – Pipeline Review, H2 2012
12/26/2012 | published by: Global Markets Direct
... development for Other Neurologic Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Other Neurologic Disorders. Other Neurologic Disorders - ...
|
more...
|
$2,000.00
|
Research Report on China's Antidepressant Market, 2013-2017
12/26/2012 | published by: China Research and Intelligence Co., Ltd.
... million people commit suicide every year because of depression. Depression becomes a health crisis worldwide. Depression (also DEP) is a set of mood disorders or affective disorders with the main symptom of depression caused by ...
|
more...
|
$2,800.00
|
Seizures – Pipeline Review, H2 2012
12/26/2012 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Seizures. Seizures - Pipeline Review, Half Year is built using data and information ...
|
more...
|
$2,000.00
|
Central Nervous System (CNS) Tumor – Pipeline Review, H2 2012
12/26/2012 | published by: Global Markets Direct
... information on the therapeutic development for Central Nervous System (CNS) Tumor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Central ...
|
more...
|
$2,500.00
|
Mania – Pipeline Review, H2 2012
12/26/2012 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mania. Mania - Pipeline Review, Half Year is built using data and information ...
|
more...
|
$2,000.00
|
Cerebral Infarction (Brain Infarction) – Pipeline Review, H2 2012
12/26/2012 | published by: Global Markets Direct
... the therapeutic development for Cerebral Infarction (Brain Infarction), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cerebral Infarction (Brain Infarction). ...
|
more...
|
$2,000.00
|
General Anxiety Disorder – Pipeline Review, H2 2012
12/26/2012 | published by: Global Markets Direct
... development for General Anxiety Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for General Anxiety Disorder. General Anxiety Disorder - ...
|
more...
|
$2,000.00
|
Neurology – Pipeline Review, H2 2012
12/26/2012 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neurology. Neurology - Pipeline Review, Half Year is built using data and information ...
|
more...
|
$2,500.00
|
Cognitive Disorders – Pipeline Review, H2 2012
12/26/2012 | published by: Global Markets Direct
... Cognitive Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cognitive Disorders. Cognitive Disorders - Pipeline Review, Half Year is ...
|
more...
|
$2,000.00
|
2012 Pharmaceuticals Research Review
12/1/2012 | published by: BCC Research
... human antifungal therapeutics with a heavy focus on therapeutics in early development. Profiles of manufacturers of leading asthma and chronic obstructive pulmonary disease (COPD) prescription drugs. Comprehensive analysis of the market for genitourinary drugs on ...
|
more...
|
$950.00
|
Brain Ischemia – Pipeline Review, H2 2012
11/28/2012 | published by: Global Markets Direct
... Brain Ischemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Brain Ischemia. Brain Ischemia - Pipeline Review, Half Year is ...
|
more...
|
$2,000.00
|
Obsessive-Compulsive Disorder – Pipeline Review, H2 2012
11/28/2012 | published by: Global Markets Direct
... Obsessive-Compulsive Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Obsessive-Compulsive Disorder. Obsessive-Compulsive Disorder - Pipeline Review, Half Year is ...
|
more...
|
$2,000.00
|
Tinnitus – Pipeline Review, H2 2012
11/28/2012 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Tinnitus. Tinnitus - Pipeline Review, Half Year is built using data and information ...
|
more...
|
$2,000.00
|
Generalized Seizures – Pipeline Review, H2 2012
11/28/2012 | published by: Global Markets Direct
... Generalized Seizures, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Generalized Seizures. Generalized Seizures - Pipeline Review, Half Year is ...
|
more...
|
$2,000.00
|
|
|
$2,500.00
|
< prev 1 2 3 4 5 6 7 8 9 10 next >
|